Toggle Nav
  • Menu
  • Setting


Catalog No.
Reverse transcriptase inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
In stock
In stock
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors


Zalcitabine is a nucleoside analog reverse transcriptase inhibitor (NRTI).

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
Cas No.7481-89-2
Solubilityinsoluble in EtOH; ≥10.65 mg/mL in DMSO with gentle warming; ≥15.87 mg/mL in H2O with ultrasonic
Chemical Name4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
SDFDownload SDF
Shipping ConditionShip with blue ice, or upon other requests.
General tipsFor obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while.


Cell experiment:[1]

Cell lines

3201 (feline lymphoid) cells, 81C (sarcoma-positive, leukemia-negative feline lung fibroblast) cells, and primary feline bone marrow cells

Reaction Conditions

0 ~ 384 μM zalcitabine


Zalcitabine (5 ~ 10 μM) inhibited feline leukemia virus (FeLV) infection of feline lymphoid cells by greater than 80%, while 6.07 ~ 12.13 μM zalcitabine was required to similarly inhibit infection of feline fibroblasts. However, 43 ~ 384 μM zalcitabine was needed to inhibit FeLV infection of primary bone marrow cells by greater than 80%.

Animal experiment:[1]

Animal models

Cats challenged intravenously with FeLV 1 ~ 3 days after drug treatment began

Dosage form

22, 15, 10, and 5 mg/kg per h

Administered by continuous intravenous infusion for 28 days


Doses of 22 and 15 mg/kg per h were extremely toxic, causing death in 8 of 10 cats. The 10 mg/kg per h dose was slightly toxic, causing chronic progressive thrombocytopenia over the 28-day treatment period. Of 10 cats given 10 or 5 mg of zalcitabine per kg per h, only one was completely protected from FeLV antigenemia. However, conversion to positive FeLV antigenemia status was delayed by 2 ~ 7 weeks in seven of nine remaining animals.


The technical data provided above is for reference only.


1. Polas PJ, Swenson CL, Sams R, et al. In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrobial Agents and Chemotherapy, 1990, 34(7): 1414-1421.

Quality Control